Several recently published studies have suggested that patients who undergo ABO mismatched hematopoietic stem cell transplantation may be at increased risk for relapse, graft-versus-host disease, transplant-related mortality, and/or all-cause mortality. To investigate this issue further, we analyzed potential associations between the donor-recipient ABO mismatch pattern and the above outcome measures among 240 consecutive patients who underwent allogeneic hematopoietic stem cell transplantation at our institution. Our analyses uncovered no significant associations between donor-recipient ABO mismatch pattern and overall survival, event-free survival, transplant-related mortality, incidence of acute graftversus-host disease (GVHD), or incidence of chronic GVHD. Our data do not support recent assertions that donor-recipient ABO mismatching is a major risk factor for patients undergoing allogeneic transplant, nor do they support recent assertions that ABO matching should be an important consideration in selecting allogeneic hematopoietic stem cell donors.
Introduction
It is generally agreed that donor-recipient ABO mismatching in the setting of allogeneic hematopoietic stem cell transplantation is associated with an increased incidence of delayed erythropoietic recovery, pure red cell aplasia, and alloimmune hemolytic anemia. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, the literature contains strikingly disparate opinions regarding the potential effect of ABO mismatching on other important outcome parameters including the incidence of death, relapse, graft-versus-host disease (GVHD), and transplant-related-mortality. Specifically, various investigators have concluded that ABO mismatching increases, [13] [14] [15] [16] [17] [18] [19] [20] [21] does not affect, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] or decreases, [33] [34] the incidence of one or more of the latter events.
We hypothesized that the wide disparity of opinion regarding the association between donor-recipient ABO mismatching and the latter outcome measures could be partially or wholly attributable to so-called 'publication bias'. [35] [36] [37] [38] [39] [40] [41] [42] Publication bias is a well-documented and highly prevalent phenomenon related to the fact that each individual statistical test that is performed has approximately a 5% risk of detecting a false-positive association as a result of chance alone. When multiple institutions investigate essentially the same issue, and/or when individual authors examine multiple hypotheses in the context of a single study, there is strong evidence to suggest that statistically significant associations are frequently observed as a result of chance alone, and that such associations are far more likely to be published in comparison with studies that do happen not be associated with statistically significant results. [35] [36] [37] [38] [39] [40] [41] [42] The routine availability of donor and recipient ABO typing, the relative ease of analyzing correlations with respect to donor-recipient ABO mismatch patterns, the large number of papers in the literature that have addressed this issue, and the predominance of papers in the literature that have not clearly specified a single primary statistical end point with respect to these issues all led us to postulate that publication bias could be playing an important role in the ongoing controversy regarding the importance of ABO mismatching in the setting of allogeneic hematopoietic stem cell transplantation.
In order to address to above issues, we initiated the current study by informing our Institutional Research Review Board, in writing, that our study would focus on a single primary statistical end point, that is, the potential effect of receiving an ABO mismatched transplant on overall survival. In addition, we utilized formal statistical multiple comparison adjustment techniques to reduce the risk of reporting false-positive associations relative to our secondary end points, that is, potential associations between ABO mismatch pattern and event-free survival, transplant-related mortality, acute GVHD, and chronic GVHD. To our knowledge the present study is the only investigation of ABO mismatching in the hematopoietic stem cell transplant literature that has both formally specified a single primary statistical end point before the initiation of the analysis, and used formal statistical adjustments to reduce the risk of detecting false positive associations with respect to the analysis of additional end points. Outcome following ABO-mismatched BMT TR Klumpp et al AB-into-A or A-into-AB transplants were also permitted to receive type A red cells in the early pretransplant period, whereas recipients of AB-into-B or B-into-AB grafts were also permitted to receive type B red cells. All transplants were carried out according to Temple University Institutional Review Board (IRB) approved protocols or written in-house protocols. As detailed in Table 1 , the vast majority of transplants were carried out for patients with commonly transplanted diagnoses utilizing commonly utilized conditioning regimens, GVHD prophylactic regimens, etc. T-cell depletion techniques were not utilized.
Patients and methods

We
The primary statistical end point of the study was the association between the donor-recipient ABO mismatch pattern and the respective actuarial overall survival estimates. The primary statistical end point was assessed with a log-rank analysis in which the ABO mismatch pattern was treated as a non-ordered categorical variable as illustrated in Table 2 . Additional log-rank analyses were performed in which the ABO mismatch pattern was treated as a series of binary variables in which each individual pattern (i.e., ABO matched, major mismatched, minor mismatched, and bidirectionally mismatched) was examined individually, and in which the ABO mismatch pattern was treated as a rank-ordered variable in which the ranks were assigned based on the observed actuarial median survival estimates within the respective strata. Multivariate Cox proportional hazards analysis was utilized to correct for potential confounding effects of Eastern Cooperative Oncology Group (ECOG) performance status, recipient age, sex mismatch pattern (female-into-male versus other), the Seattle Disease Risk Index, 43 donor age, donor category (HLA-identical sibling versus matched unrelated donor versus mismatched unrelated donor), conditioning regimen category (myeloablative versus submyeloablative), stem cell source (marrow versus peripheral blood), donor and recipient cytomegalovirus (CMV) status, infused CD34 cell dose, immediate pretransplant left ventricular ejection fraction, forced expiratory volume in one second (FEV1), carbon monoxide diffusing capacity (DLCO), creatinine, and bilirubin. The statistical power of the study to detect the effect of ABO mismatching on overall survival was calculated in accordance with the methodology of Goodman and Berlin 44 (results presented below). Secondary end points included potential associations between ABO mismatch pattern and event-free survival (where events included relapse, progression or death from any cause), transplant-related mortality, maximum observed acute GVHD grade, and maximum observed chronic GVHD grade. Acute GVHD was graded according to the consensus conference on acute GVHD grading, 45 and chronic GVHD was graded according to the traditional Seattle criteria. 46 In order to reduce the risk of detecting false-positive associations due to the examination of multiple end points, the SAS PROC MULTTEST implementation of the Hochberg technique 47 was utilized to adjust the raw P-values. Analyses involving categorical end points were carried out with the w 2 test. All P-values reported are two-sided, and 0.05 was taken as the minimum level of statistical significance. All data management and data analyses were carried out with SAS statistical Software, versions 8.2 and 9.1. This study was approved by the Temple University Institutional Review Board. Table 1 summarizes the patient, donor, and transplant characteristics. As shown, the median age of the patients at the time of transplant was 43 years, and the patient population included 130 male patients and 110 female patients. The most commonly transplanted diagnoses included acute myelogenous leukemia, chronic myelo genous leukemia, and non-Hodgkin lymphoma. Peripheral blood derived hematopoietic stem cells were utilized in 57% of the transplants, whereas bone marrow was utilized in 43%. Myeloablative conditioning regimens were used in 65% of the procedures, whereas submyeloablative regimens were utilized in 35%. In all, 75% of the transplants utilized HLA-identical sibling donors, 15% utilized HLA-matched unrelated donors, 5% utilized HLA-nonidentical siblings, 3% utilized HLA-mismatched unrelated donors, and 1% utilized HLA-matched family members other than siblings. None of the distributions of any of the above parameters showed statistically significant variations with respect to the ABO mismatch pattern. Figure 1 illustrates the results of the primary statistical analysis, that is, the log-rank analysis examining the potential association between the ABO mismatch pattern and the respective actuarial overall survival estimates. As shown, there is no indication of a significant difference between the actuarial survival estimates for patients receiving ABO identical transplants versus major, minor, or bidirectionally mismatched transplants (P ¼ 0.53). Outcome following ABO-mismatched BMT Table 2 summarizes the numerical details of the primary statistical analysis and related analyses. As detailed in the table, the ABO mismatch pattern was not predictive of overall survival regardless of how the ABO mismatch pattern was stratified, that is, matched versus mismatched, major mismatched versus other, minor mismatched versus other, bidirectionally mismatched versus other, or testing for homogeneity across strata with respect to the four possible ABO mismatch patterns. The latter analysis was not statistically significant regardless of whether the ABO mismatch pattern was treated as a non-ordered categorical variable or as a rank-order variable in which the ranks were assigned based on the observed overall survival within each stratum.
Results
In order to evaluate the statistical power of the study to detect the effect of ABO mismatch pattern on overall survival, we calculated 95% confidence intervals for the differences in the respective 5-year actuarial survival estimates. These intervals were À15 to þ 14%, À10 to þ 27%, À25 to þ 13%, and À37 to þ 23% for the effect of any type of ABO mismatch, major ABO mismatch, minor ABO mismatch, and bidirectional ABO mismatch, respectively, on the 5-year actuarial overall survival rate.
In order to further investigate the above issues, we examined a number of multivariate Cox proportional hazards models involving the primary statistical end point. The only factors independently predictive of overall survival were the Seattle Disease Risk Index, 43 the donor and recipient CMV status, and the recipient's cardiac and pulmonary function status before transplant. None of the schema for stratifying the donor-recipient ABO mismatch pattern listed in Table 2 was independently predictive of overall survival in any of the multivariate models examined. Table 3 summarizes the analyses of the secondary end points. As shown, we found no evidence of an association between ABO mismatch pattern and event-free survival, transplant-related mortality, incidence of grade 2 or higher acute GVHD, or incidence of extensive chronic GVHD.
Discussion
The well-established importance of donor-recipient ABO compatibility in the solid organ transplant literature [48] [49] [50] has led many bone marrow transplant programs to examine the potential importance of donor-recipient ABO-mismatching in the bone marrow transplant setting, and a number of groups have indeed reported apparent associations between various donor-recipient ABO mismatch patterns and transplant-related mortality, overall survival, relapse rates and/or GVHD. [13] [14] [15] [16] [17] [18] [19] [20] [21] 33, 34 However, the relative ease of testing for such correlations, the well-known and highly prevalent phenomenon of publication bias, and the presence of a number of studies in the literature that have failed to confirm such correlations [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] led us to hypothesize that publication bias itself may be partly or wholly responsible for the appearance of such reports in the literature. To our knowledge, the current study is the only investigation of these issues in the BMT literature in which the authors have specified a single, precisely defined primary statistical end point before initiating the actual analysis, and used formal statistical adjustments to reduce the risk of reporting false-positive associations involving secondary end points. It is therefore of interest that we were unable to confirm a correlation between donor-recipient ABO mismatching and the primary end point of overall survival, nor were we able to corroborate reports of associations between ABO mismatching and any of our secondary end points, that is, event-free survival, transplant-related mortality, acute GVHD, or chronic GVHD.
It is important to note that the findings of the current study are supported by the recently reported large study from the Center for International Blood and Marrow Transplant Research (CIBMTR), which appeared in the literature while the current study was already underway. 32 However, the current study was more conservatively executed than the CIBMTR study because the latter study specified multiple primary statistical end points at the Table 3 Analysis of relationship between ABO mismatch pattern, event-free survival, transplant-related mortality, and graft-versus-host disease P-value Figure 1 Overall survival according to ABO mismatch pattern.
Outcome following ABO-mismatched BMT TR Klumpp et al outset and did not specify or utilize any formal adjustments for multiple comparisons involving the multiple primary and secondary end points examined. In addition, the current study may be more widely applicable than the CIBMTR study because the CIBMTR study included only patients with early-stage leukemia, whereas the current study included an unselected consecutive series of transplants and thus represents all of the commonly transplanted diagnoses. We and others have hypothesized 13, 15, 16, 26 that minor ABO mismatches between BMT donors and recipients might be associated with an increased incidence of GVHD given the importance of the ABO system in the solid organ transplant setting and given the expression of recipientderived ABO antigens on essentially all host nucleated cells, which could potentially serve as a target for incoming donor T-cells. However, neither the current study nor the large recently published CIBMTR study 32 just mentioned supports this hypothesis. To our knowledge there are no widely accepted explanations for this seemingly paradoxical observation.
Most of the studies in this area, including the present study, have had limited statistical power to detect associations involving bidirectional ABO mismatches due the relatively small number of patients in this subset. It is therefore of interest that both the present study and at least one other study in this area 17 have reported at least a trend toward inferior overall survival among patients receiving bidirectionally ABO mismatched transplants. A larger study designed specifically to examine the issue of bidirectionally mismatched transplants therefore seems warranted.
In summary, our data do not support recently published reports that donor-recipient ABO mismatching among patients undergoing hematopoietic stem cell transplantation are associated with major increases in the risk of death, relapse, transplant-related mortality, acute GVHD, and/or chronic GVHD. In contrast, our data appear to support our hypothesis that the appearance of the latter reports in the peer-reviewed literature may be at least partly attributable to publication bias. Therefore, it appears that donor-recipient ABO matching should not be a major consideration when selecting among possible hematopoietic stem cell donors.
